Celtaxsys cystic fibrosis drug reduces key symptom in mid-stage study

Privately held Celtaxsys Inc said on Thursday a mid-stage trial testing its experimental cystic fibrosis treatment was successful in reducing a key symptom of the genetic lung disease, but did not improve lung function.